Inhibrx Biosciences, Inc.盘中异动早盘急速拉升7.41%报14.13美元_老虎社区_美港股上老虎

Inhibrx Biosciences, Inc.盘中异动早盘急速拉升7.41%报14.13美元

市场透视2025-01-27

北京时间2025年01月27日23时02分，Inhibrx Biosciences, Inc.（INBX.us）股票出现异动，股价快速上涨7.41%。截至发稿，该股报14.13美元/股，成交量1.2927万股，换手率0.09%，振幅3.50%。最近的财报数据显示，该股实现营业收入0.00美元，净利润-43.86百万美元，每股收益-3.03美元，毛利-760000.00美元，市盈率0.11倍。机构...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2506054503?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-01-27 23:02","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2506054503","market":"us","top_or_hot":-1,"title":"Inhibrx Biosciences, Inc.盘中异动 早盘急速拉升7.41%报14.13美元","media":"市场透视","content":"<div>\n<p>北京时间2025年01月27日23时02分，Inhibrx Biosciences, Inc.（INBX.us）股票出现异动，股价快速上涨7.41%。截至发稿，该股报14.13美元/股，成交量1.2927万股，换手率0.09%，振幅3.50%。最近的财报数据显示，该股实现营业收入0.00美元，净利润-43.86百万美元，每股收益-3.03美元，毛利-760000.00美元，市盈率0.11倍。机构...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501272302149874b4f4&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Inhibrx Biosciences, Inc.盘中异动 早盘急速拉升7.41%报14.13美元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInhibrx Biosciences, Inc.盘中异动 早盘急速拉升7.41%报14.13美元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-27 23:02 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501272302149874b4f4&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>北京时间2025年01月27日23时02分，Inhibrx Biosciences, Inc.（INBX.us）股票出现异动，股价快速上涨7.41%。截至发稿，该股报14.13美元/股，成交量1.2927万股，换手率0.09%，振幅3.50%。最近的财报数据显示，该股实现营业收入0.00美元，净利润-43.86百万美元，每股收益-3.03美元，毛利-760000.00美元，市盈率0.11倍。机构...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501272302149874b4f4&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501272302149874b4f4&s=b","article_id":"2506054503","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501272302149874b4f4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2506054503","pubTimestamp":1737990134,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"北京时间2025年01月27日23时02分，Inhibrx Biosciences, Inc.股票出现异动，股价快速上涨7.41%。截至发稿，该股报14.13美元/股，成交量1.2927万股，换手率0.09%，振幅3.50%。Inhibrx Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.88%。Inhibrx Biosciences, Inc.公司简介：Inhibrx Biosciences Inc是一家临床阶段的生物制药公司，利用其专有的模块化蛋白质工程平台开发了一系列新型生物治疗候选药物。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4139":"生物科技","INBX":"Inhibrx Biosciences"},"translate_title":"Inhibrx Biosciences, Inc. surged 7.41% to $14.13 in early trading","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INBX":1},"content_text":"北京时间2025年01月27日23时02分，Inhibrx Biosciences, Inc.（INBX.us）股票出现异动，股价快速上涨7.41%。截至发稿，该股报14.13美元/股，成交量1.2927万股，换手率0.09%，振幅3.50%。最近的财报数据显示，该股实现营业收入0.00美元，净利润-43.86百万美元，每股收益-3.03美元，毛利-760000.00美元，市盈率0.11倍。机构评级方面，在所有2家参与评级的机构中，100%的券商给予持有建议，无券商给予买入、卖出建议。Inhibrx Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.88%。其相关个股中，Akero Therapeutics, Inc.、Onconetix, Inc.、89Bio, Inc.涨幅较大，Onconetix, Inc.、Evaxion Biotech As、Dogwood Therapeutics, Inc.较为活跃，换手率分别为1445.98%、171.68%、107.14%，振幅较大的相关个股有阿诺医药、Onconetix, Inc.、Conduit Pharmaceuticals Inc C/Wts 22/09/2028(To Pur Com)，振幅分别为98.54%、85.35%、65.16%。Inhibrx Biosciences, Inc.公司简介：Inhibrx Biosciences Inc是一家临床阶段的生物制药公司，利用其专有的模块化蛋白质工程平台开发了一系列新型生物治疗候选药物。其临床治疗候选药物包括INBRX-109和INBRX-106，这两种药物均采用多价形式，可以以靶向为中心的方式优化精确的价态，以调节专家认为是主要的激动剂功能。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}